Delivery of therapeutic proteins to the systemic circulation using gene therapy has the potential to improve the efficacy, duration, convenience, and cost effectiveness of chronic disease treatment by replacing the frequent and often invasive administrations of recombinant proteins with infrequent delivery of the corresponding therapeutic genes. For rheumatoid arthritis, long-lasting systemic production of a therapeutic protein such as the anti-tumor necrosis factor alpha (anti-TNF-␣) inhibitor etanercept (TNF-␣ receptor-immunoglobulin G1 [IgG1] Fc fusion [TNFR:Fc]), by noninvasive administration of gene therapy vectors, may improve the pharmacokinetics of this relatively short-lived protein.
Recombinant adeno-associated virus (AAV) vector is one of the most promising delivery vehicles under development for gene therapy which has been shown to efficiently direct longterm transgene expression in multiple tissues, including skeletal muscle, liver, brain, and retina, with little or no inflammation or cellular immune response (1, 8, 26, 30, 35, 41, 42, 49, 53) . Although most of the earlier studies were carried out with vectors based on AAV serotype 2 (AAV2), recent experiments with vectors derived from alternate primate AAV serotypes, of which at least eight have been isolated to date (11, 12, 20, 34, 39, 50) , have demonstrated marked increase in transduction efficiency of various target tissues due to distinct mechanisms of tropism, uptake, and trafficking (5, 16, 28, 47, 48, 52) . In vitro and in vivo studies with AAV5 have demonstrated improved binding and transduction of murine lung airway epithelia compared with that of AAV2 (52) . Within the brain, while vectors derived from AAV2 efficiently transduce neurons in close proximity to the site of administration, AAV5-based vectors are capable of diffusion within the mouse striatum well beyond the injection site and have demonstrated efficient gene transfer to the ependymal cells of the ventricles and the cerebral hemisphere (14) . AAV1 and AAV7 vectors appear to be the most efficient gene transfer vehicles in skeletal muscle transduction compared with AAV2, -3, -4, and -5 vectors (10, 20, 50) , whereas AAV vectors containing the type 5 and 8 capsids have been shown to direct high levels of transgene expression in liver (20, 32, 40) .
Since the tissue tropism of each viral serotype is determined by the interaction of the capsid with a distinct receptor and/or coreceptor(s) on target cells, pseudotyped vectors can be efficiently produced by cross-packaging of an AAV2 vector genome into the capsids of other serotypes (15, 37, 38, 45, 46, 48) .
The lung can potentially be employed as a metabolic factory for the ectopic production and secretion of therapeutic proteins into the circulation because it has one of the most expan-sive epithelium-blood capillary networks and is easily accessible for noninvasive gene delivery. In addition, the lung offers a large number of target cells with adequate access to the blood. In the context of recombinant AAV, successful in vivo airway gene transfer with AAV vectors, carrying reporter genes and therapeutic genes including the cystic fibrosis transmembrane regulator transgene, has been demonstrated in multiple species, including rabbits (6, 23) , mice (24) , nonhuman primates (2, 7, 13, 17) , and human cystic fibrosis patients (3, 18, 33) . In addition, the lung appears to be an ideal target organ in terms of safety parameters, given the lack of observable AAV vector DNA biodistribution to gonads and given its decreased likelihood of generating immune responses compared to muscle or liver following the delivery of AAV vectors (13, 17, 51) .
The concept of using the lung for the ectopic production of secreted proteins has recently been employed by Auricchio and colleages, who demonstrated that intranasal delivery of therapeutic genes, including erythropoietin and factor IX, to mice by using pseudotyped AAV vectors led to long-term and apparently functional secretion of the corresponding proteins into the systemic circulation (4) .
In this report, we evaluated and compared delivery of the TNFR:Fc fusion gene to the lung by single and repeat administrations of pseudotyped AAV vectors of alternate serotypes as a means to achieve systemic distribution of a TNFR:Fc fusion protein. Here, we show that in rats, pseudotyped AAV5 (AAV [2/5] ) vector is more efficient than AAV[2/1] or AAV [2/2] . However, in mice AAV[2/2] appears to be as efficient as AAV [2/5] in mediating long-term secretion of TNFR:Fc protein from the lung to the systemic circulation, albeit at different initial kinetics of transduction. In addition, we examined the types of lung cells transduced by AAV vectors pseudotyped with type 2 or 5 capsid and provide evidence to suggest that airway epithelium is the primary source of TNFR:Fc protein secretion to the blood. Finally, AAV [2/5] could be readministered to animals that were previously treated with either the same or an alternate pseudotyped vector and efficiently mediate secretion of TNFR:Fc protein to the circulation.
MATERIALS AND METHODS
Cells. Human 293 (22) and HeLa (21) cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker; Cambrex, Walkersville, Md.) supplemented with 100 U of penicillin G/ml, 100 g of streptomycin/ml, 4.5 mg of glucose/ml, 4 mM L-glutamine, and 10% heat-inactivated (55°C; 30 min) fetal bovine serum (HyClone, Logan, Utah) in a humidified atmosphere of air with 10% CO 2 at 37°C.
Plasmids. Plasmid pAAVCMV-EGFP contains the enhanced green fluorescent protein (EGFP) gene under the control of the human cytomegalovirus (CMV) major immediate-early gene enhancer/promoter region, a chimeric human ␤-globin splice donor-human Ig splice acceptor site, and a bovine growth hormone (BGH) poly(A) signal. The EGFP transcriptional unit is flanked at each end by the AAV2 145-bp inverted terminal repeat sequence, derived from pAV2 (27, 43) . The structure of plasmid pAAVCMV-hFIX is essentially the same as that of pAAVCMV-EGFP, except that human factor IX (hFIX) cDNA was substituted for the EGFP sequences. Construction of plasmid pAAVCMV-TNFR:Fc was previously described (9) . Plasmid pAAVCC10-TNFR:Fc was constructed as follows. A 326-bp DNA fragment, containing the rat CC10 promoter (44) , was amplified by PCR from rat lung genomic DNA with an upstream primer sequence, 5Ј-CTCGAGCAATTGCTTCCCGGAACCT-3Ј, and a downstream primer, 5Ј-GCGGCCGCATGTGTGGGTATGCGTGTGGC-3Ј, containing unique XhoI and NotI restriction sites at the 5Ј and 3Ј ends, respectively. The 326-bp PCR product was cloned into plasmid pCR2.1-TOPO TA (Invitrogen, Carlsbad, Calif.) and propagated in Escherichia coli TOP10 cells. Plasmid pAAVCMV-TNFR:Fc was digested with XhoI and NotI to remove the CMV immediate-early enhancer/promoter. The 326-bp CC10 promoter was liberated from plasmid pCR2.1CC10 via XhoI/NotI digestion and ligated into the XhoI/ NotI sites in plasmid pAAVCMV-TNFR:Fc. The trans-packaging plasmids pBSHSPR2C1 and pBSHSPR2C5 were constructed as follows. Genomic DNA was extracted from AAV1 (American Type Culture Collection, Manassas, Va.), and the cap encoding sequence was amplified by PCR with Pfx polymerase (Invitrogen). The AAV2 cap gene was excised from the AAV2 helper plasmid pBSHSPRC2.3 and replaced with the amplified AAV1 cap sequence with an SwaI restriction site in the rep-cap intergenic junction and a BsrGI site engineered just upstream of the AAV2 poly(A) signal. The resulting trans-packaging construct, pBSHSPR2C1, contains the AAV2 rep gene under the control of a minimal eukaryotic promoter and the AAV1 cap open reading frame positioned between the AAV2 rep-cap intergenic junction and the AAV2 poly(A) signal. The trans-packaging construct, pBSHSPR2C5, containing the AAV2 rep and AAV5 cap genes, was assembled similarly except that the template for AAV5 cap was the plasmid pACK2/5 (25) , and the insertion sites in pBSHSPRC2.3 were SwaI/XbaI. The plasmid pAd Helper 4.1 expresses the E2a, E4-orf6, and VA genes of adenovirus type 5 (Ad5).
Vector production and purification. Recombinant AAV vectors were produced by a standard calcium phosphate transfection method in adherent human 293 cells, using the Ad helper, trans-packaging, and AAV vector plasmids. Briefly, cells were seeded in 225-cm 2 T-flasks and grown to subconfluency in complete DMEM (BioWhittaker). Plasmids pAd helper 4.1, pBS-HSP-RC2.3 (or pBS-HSP-R2C5 or pBS-HSP-R2C1), and AAV vector plasmid (i.e., pAAVCMV-TNFR:Fc) were added (2:2:1 molar ratio) to a 300 mM CaCl 2 solution. To form a calcium phosphate precipitate, the plasmid mixture was added to a 2ϫ HBS buffer (280 mM NaCl, 1.5 mM Na 2 PO 4 , 5 mM HEPES [pH 7.1]), incubated for 30 s, and then added directly onto the 293 cell monolayer. The cells were incubated for 6 to 8 h at 37°C, after which the medium was aspirated and replenished with fresh complete but serum-free DMEM. Three days posttransfection, the cells were lysed by the addition of deoxycholate (Fisher, Houston, Tex.) to a final concentration of 0.5%, releasing all cellular and nuclear contents into the solution. The cellular DNA was digested by the addition of Benzonase (EM Sciences, Gibbstown, N.J.) at a concentration of 10 U/ml for 1 h at 37°C. Tween 20 (Fisher) was added to a final concentration of 1% with a further incubation for 60 min at 37°C, followed by the addition of NaCl to a final concentration of 1 M, before clarification through depth filters (Millipore, Bedford, Mass.). Clarified lysates were concentrated 15-to 20-fold by tangential flow filtration with Pellicon 2 minicassettes (110-kDa molecular mass cut off; Fisher) and were exchanged against formulation buffer (20 mM Tris [pH 8.0], 0.2 M NaCl, 2 mM MgCl 2 , and 2% glycerol). The lysates were diluted through a 0.45-m-pore-size Pall suporcap filter unit (Gelman; Fisher) and stored at Ϫ80°C. The harvested lysates were purified by ion-exchange chromatography essentially as previously described (29, 54) . Vector-containing elutes were formulated in a buffer containing 20 mM Tris (pH 8.0), 0.2 M NaCl, 2 mM MgCl 2 , and 2% glycerol and aseptically filtered. Final vector preparations were Ͼ95% pure, with low endotoxin levels (Ͻ0.5 endotoxin units/ml). The purified vectors were nonaggregated, as determined by dynamic laser light-scattering analysis with a DynaPro-99 instrument (Protein Solutions, High Wycombe, United Kingdom). Vector titers were determined by real-time PCR with an Applied Biosystems Prism 7900 sequence detector (Perkin-Elmer, Foster City, Calif.) and were between 5 ϫ 10 12 and 20 ϫ 10 12 DNase-resistent particles (DRP)/ml. Vector infectivity was assessed in a 50% tissue culture infective dose assay with the HeLa-based B50 cell line (19 Ϫ/Ϫ mice, 6 to 8 weeks old, were purchased from Jackson Laboratories (Bar Harbor, Maine). Animals were maintained and treated in accordance with the Institutional Animal Care and Use Committee of Targeted Genetics Corporation and the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animals were allowed to acclimate 7 days before experimentation and were fed water and chow ad libitum. Animals were anesthetized with isoflurane (5% with O 2 for induction and 3% for maintenance) (Abbott Laboratories, North Chicago, Ill.). For endotracheal administrations, a dissecting microscope light was placed at the ventral neck to allow visualization of the tracheal opening, with the mouth opened and the tongue extended to visualize the larynx. A catheter stylet (Cathlon; Johnson & Johnson, Arlington, Tex.) was advanced when the vocal chords were relaxed and the tracheal opening was visible. The stylet was then withdrawn and a syringe containing either vehicle or AAV vector (100 and 300 l for mice and rats, respectively) was attached to the catheter. Following vector administration, a bolus of air (approximately 100 to 200 l) was pushed through to clear the catheter of any remaining vector solution. Animals were placed in a recovery cage and monitored for signs of respiratory distress. For intramuscular administration, rats were anesthetized as described above. The quadriceps was visualized, the injection site was sterilized, and the rats were injected intramuscularly with vector with a 0.5-ml insulin syringe and a 28.5-gauge needle. Each animal was injected with a total volume of 150 l of vector, with each hind limb receiving 75 l. After the procedure, the animals were placed in a recovery cage and observed for normal ambulation.
Immunohistochemical analysis of EGFP expression. EGFP expression in the rat lung was assessed 42 days following endotracheal administration of either AAV[2/2]CMV-EGFP or AAV[2/5]CMV-EGFP vector (at a dose of 10 12 DRP). Briefly, rats were humanely sacrificed, and lungs were perfused and fixed overnight with 10% neutral-buffered-formalin (Sigma, St. Louis, Mo.). Tissues were then processed and embedded in paraffin. Sections of 0.5-m tissue were cut, placed on poly-L-lysine-coated slides, and processed for immunohistochemical analysis of EGFP protein as follows. The sections were deparaffinized and rehydrated in a graded series of ethanol washes. Slides underwent antigen retrieval in citrate buffer (pH 6.0) in a steamer for 30 min prior to being blocked in the peroxidase block of the Rabbit/Peroxidase EnVisionϩ System (DAKO, Carpinteria, Calif.). The slides were washed three times with phosphate-buffered saline (PBS) and incubated for 1 h at room temperature with either anti-EGFP antibody (1:2,000 dilution; Molecular Probes, Eugene, Oreg.) or the isotype control rabbit IgG antibody whole-molecule antibody (1:20,000 dilution; Jackson ImmunoResearch, West Grove, Pa.) Both anti-EGFP and isotype control antibodies were at a concentration of 2 g/ml. After being washed with PBS, the slides were incubated for 30 min at room temperature with labeled polymer (DAKO) according to the manufacturer's directions. The peroxidase-catalyzed product was visualized with 3,3Ј-diaminobenzidine (DAKO). Unless otherwise noted, the slides were rinsed between steps three times for 2 min each in PBS (pH 7.6). After light counterstaining with methylene blue (Sigma), the slides were dehydrated in sequential concentrations of ethanol and xylene, and the coverslips were mounted with Permount (Fisher).
Anti-AAV capsid-neutralizing antibody assay. Anti-AAV2 or AAV1 capsidneutralizing antibody titers were determined by analyzing the ability of serum from either AAV [ 3 DRP/cell) of the corresponding serotype for 1 h at 37°C. The cells were infected with Ad5 (multiplicity of infection ϭ 2.5) and the serum-AAVCMV-EGFP mixtures were added to the cells. Cells were incubated for 48 h, and the expression of EGFP was analyzed by FluoroImaging (Cytofluor 4000; PerSeptive Biosystems, Framingham, Mass.). The neutralizing antibody titer was calculated as the highest dilution of serum at which there was 50% fluorescence. Anti-AAV5 capsid-neutralizing antibody titers were determined as described above, except that HeLa cells were substituted for the 293 cells and AAV[2/5]CMV-EGFP vector was used in the assay.
RT-PCR analysis of TNFR:Fc mRNA. (i) RNA isolation. Rat lung tissues were ground to a fine powder in liquid nitrogen with a 6750 Freezer/Mill (Spex CertiPrep, Metuchen, N.J.). Samples were kept frozen (Ϫ70°C) until aliquoted for RNA isolation. Total RNA was isolated with the RNeasy Fibrous Tissue Kit (QIAGEN, Valencia, Calif.) according to the manufacturer's protocol. This included the use of the optional on-column DNase step. After isolation, RNA was quantified with a standard spectrophotometer at A 260 absorbance.
(ii) cDNA synthesis. For first-strand cDNA synthesis, the sample size per single replicate was 650 ng of RNA per 20 l of reaction mixture (56.65 ng/l) containing 0.1 volume 10ϫ buffer (Invitrogen), 2.5 mM MgCl 2 , 0.5 mM deoxynucleotide triphosphates, 10 mM dithiothreitol, 10 U of RNase OUT, 50 U of Superscript II RNase H Ϫ reverse transcriptase (Invitrogen), and 0.5 M primer XBrt(T) (5Ј-UUGGCAGAGGGCGACUGUCATUTTUTTTTTUTTTTTUT T-3Ј). Each sample was incubated with or without an internal spike control (synthetic TNFR:Fc RNA) to evaluate cDNA and PCR efficiencies as well as to monitor for gross inhibition in test samples. The reverse transcription (RT)-PCR was carried out at 1 cycle in a thermal cycler (GeneAmp PCR 9700; Applied Biosystems, Foster City, Calif.) for 50 min at 42°C. Following first-strand synthesis, 1 U of RNase H (Invitrogen) was added to degrade a portion of RNA from the RNA-DNA hybrid. To synthesize second-strand cDNA from the firststrand cDNA template, 0.5 M of the forward primer 2557U17 (5Ј-GCCAGC CATCTGTTGTT-3Ј), 2 U of DNA polymerase, 2.5 mM MgCl 2 , and 0.2 l of 10ϫ buffer (Invitrogen) were added to each reaction mixture. The second-strand synthesis reaction was carried out at 1 cycle for 40 min at 42°C. After secondstrand synthesis, 43 l of TE buffer (10 mM Tris, 1 mM EDTA, [pH. 8]) (Ambion, Austin, Tex.) was added to bring the reaction volume up to 65 l.
(iii) Quantitative RT-PCR. All PCRs were carried out in a 50-l volume with 10 l of the cDNA. The master mixture consisted of 0.3 M forward primer BGH (5Ј-GACCCTGGAAGGTGCCACT-3Ј), 0.3 M reverse primer Xpcr.rev (5Ј-GCACG AGGGCGACTGTCAT-3Ј), 0.1 M primer BGH.mgb (5Ј-(FAM) CCACTGTCCTTTCCTAAT-3Ј) (where FAM is 6-carboxyfluoroscein), and a 0.5 volume of a real-time 2ϫ PCR buffer (Applied Biosystems). As an endogenous control, the assay included PCR primers and probe from a Taqman Rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control reagent kit (Applied Biosystems), targeting the rat GAPDH housekeeping gene, to qualitatively assess samples for amplifiable RNA. The PCR was carried out with a real-time thermal cycler (Sequence Detection System model 7700; Applied Biosystems) according to the following program: 10 min at 50°C, 10 min at 95°C, 50 cycles of 15 s at 95°C, and 1 min at 60°C. The quantitation of the test samples was determined relative to the synthetic TNFR:Fc RNA standard curve.
Protein analyses. Serum samples were assayed for the presence of rat TNFR:Fc fusion protein with an enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well plates were coated with a goat anti-murine TNF receptor II antibody (R&D Systems, Minneapolis, Minn.) overnight at 4°C. Plates were washed three times with PBS supplemented with 0.05% Tween 20 (Fisher) and blocked with 1% bovine serum albumin (Sigma) for 3 h at room temperature on an orbital shaker. After being washed, the plates were incubated with the serum samples for 1 h at room temperature on a shaker plate. Following sample incubation, the wells were washed and incubated with a biotin-conjugated mouse anti-rat IgG1 antibody (PharMingen/BD Biosciences, San Jose, Calif.) for 1 h, washed, and then incubated with streptavidin-horseradish peroxidase (Zymed, San Francisco, Calif.) for 30 min at room temperature. The presence of rat TNFR:Fc protein was detected with the TMB colormetric substrate (Pierce, Rockford, Ill.) and stopped with 1 M sulfuric acid (Sigma). Quantitation of the amount of rat TNFR:Fc protein was based on optical density values at 450 nm (SpectrMax 250 plate reader; Molecular Devices, Sunnyvale, Calif.) compared with a standard curve of purified rat TNFR:Fc protein. The limit of detection of the assay was 2.19 ng/ml. The levels of human FIX in mouse plasma were determined by ELISA. Mouse blood was obtained in heparinized capillary tubes and was subjected to centrifugation at 800 ϫ g for 10 min. Plasma was removed and placed at Ϫ80°C until analyzed. Ninety-six-well immunoplates (Nunc, Rochester, N.Y.) were coated with affinity-purified sheep anti-hFIX IgG (KPL, Inc., Gaithersburg, Md.) overnight at 4°C. Plates were washed three times with PBS containing 0.05% Tween 20 (Fisher) and blocked with 1% bovine serum albumin (Sigma) for 3 to 4 h at room temperature. After being washed, the plates were incubated with the serum samples for 1 to 2 h at room temperature on a shaker plate. Following sample incubation, the wells were washed four times with PBS-Tween 20 and incubated with peroxidase-labeled affinity-purified sheep anti-hFIX antibody (KPL, Inc.) for 2 h, washed four times with PBS-Tween, incubated with the colorimetric substrate ABTS (2,2Ј-azino-di[3-ethylbenzthiazoline-6-sulfonate]) (Zymed) for 15 min, and then quenched with 1% sodium dodecyl sulfate. Quantitation of hFIX protein was based on optical density values at 450 nm (SpectrMax 250 plate reader; Molecular Devices) compared to a standard curve of purified recombinant hFIX protein (BeneFIX; Wyeth/Genetics Institute, Cambridge, Mass.). The limit of detection of the assay was 20 ng/ml. Statistical analysis. Data were pooled by experimental group and the means Ϯ the standard error of the mean (SEM) were calculated with the Microsoft Excel graphing and statistical program. The Student t test was conducted to determine the presence of any significant differences between two groups. P values of less than 0.05 were considered statistically significant. (Fig. 1a) . A gradual decline in serum TNFR:Fc protein expression was observed over a period of 9 months, although significant levels (mean, 48 Ϯ 2.2 ng/ml) were still detectable in the sera of rats treated at the highest vector dose 252 days postadministration (Fig. 1a) . Both AAV[2/2]CMV-TNFR:Fc and AAV[2/5]CMV-TNFR:Fc vectors elicited high titers of circulating anti-AAV 2 and anti-AAV5 capsid-neutralizing antibodies, respectively. There was no cross-neutralization between the two serotypes ( Fig. 2a and b) . (Fig. 1b) . Following peak expression, the levels of serum TNFR:Fc protein gradually declined more than threefold over (Fig. 5a) . Interestingly, at 12 weeks postvector administration (the latest time point tested), the serum levels of TNFR:Fc protein in AAV [2/2]-and AAV[2/5]-treated mice were comparable (mean, 111 Ϯ 81 and 147 Ϯ 82 ng/ml, respectively).
RESULTS

Single
To test if these results reflected differences in animal species rather than the nature of the transgene product, we also compared the plasma levels of hFIX following endotracheal administration of either AAV[2/2]CMV-hFIX (6 ϫ 10 11 DRP) or AAV[2/5]CMV-hFIX (6 ϫ 10 11 DRP) to Rag-1 Ϫ/Ϫ mice. Consistent with the previous data of TNFR:Fc protein expression in Rag-1 Ϫ/Ϫ mice, there was a gradual increase in plasma hFIX protein over a period of 7 weeks in both treatment groups, but AAV[2/5]-treated mice displayed an earlier onset and more robust expression of hFIX protein than AAV[2/2]-treated animals (Fig. 5b) . At 9 weeks after vector administration, the levels of hFIX protein in the plasma of AAV[2/2]-and AAV [2/5]-treated animals were comparable (180 Ϯ 28 and 220 Ϯ 30 ng/ml, respectively). In both vector treatment groups, expression of plasma hFIX protein remained comparable and sustained but slowly declined almost twofold over a period of 23 weeks (Fig. 5b) . Thus, it appears that there is a fundamental difference between rats and mice with respect to AAV2 transduction of the lung. In rats, AAV [ (Fig. 1a) were administered a second dose (10 12 DRP) of the same vector 253 days after the first. The results in Fig. 6a show that following a second dose of AAV [2/5]CMV-TNFR:Fc vector, the levels of serum TNFR:Fc protein gradually increased over a period of 6 months (mean, 295 Ϯ 9.5 ng/ml by day 455), but then rapidly declined more than 10-fold over a period of 6 weeks (mean, 26 Ϯ 1.5 ng/ml by day 497). Quantitative analyses of TNFR:Fc mRNA from whole lungs of three animals receiving a second dose of AAV [2/5] showed 76 TNFR:Fc mRNA molecules per cell (Fig. 7a) . These results are consistent with the data reported for mice by Auricchio and colleagues (4), indicating not only that readministration of AAV [2/5] vector to the lung in the presence of preexisting serum-neutralizing antibodies is feasible but also (Fig. 1a) . However, the peak serum levels of TNFR:Fc protein in the animals that were previously treated with AAV[2/2] were almost fourfold lower than those receiving AAV[2/5]CMV-TNFR:Fc as their first treatment (mean, 105 Ϯ 27 ng/ml and 370 Ϯ 39 ng/ml, respectively) (Fig. 6b versus Fig. 1a) . It is feasible that preexisting (Fig. 6b and 1a) . Consistent with the data shown in Fig. 1a , there was a decline of more than sevenfold within a period of 2 months to low but detectable levels of TNFR:Fc protein in the circulation (Fig. 6b) . Quantitative analysis of TNFR:Fc mRNA from whole lungs of AAV[2/2] vectortreated animals that were later given either vehicle or a second dose of AAV [2/5] showed less than 1 and 75 TNFR:Fc mRNA molecules per cell, respectively (Fig. 7a) . There was no significant difference in the amount of TNFR:Fc mRNA copies per cell in lungs of AAV[2/2]-treated animals that were given two more doses of AAV[2/5] compared with animals treated twice with AAV[2/5] alone (Fig. 7a) .
Taken together, these data demonstrate that preexisting anti-AAV2 capsid-neutralizing antibodies have no significant effect on the kinetics of transduction or the levels of transgene expression in the circulation, following delivery of a second dose of AAV[2/5]CMV-TNFR:Fc, since they appear to be comparable in both animal groups (Fig. 1a, 6b, and 7a) . (Fig. 1b) and that elicited anti-AAV1 capsidneutralizing antibody response (Fig. 2c) were given another dose of AAV[2/5]CMV-TNFR:Fc vector endotracheally on day 104; serum TNFR:Fc protein levels were monitored by ELISA. The results (Fig. 6c) (Fig. 7c) .
DISCUSSION
In this study, we examined the potential utility of AAV vector-mediated gene delivery to the lung as a means for achieving systemically circulating levels of soluble proteins with known therapeutic value. We delivered pseudotyped AAV-TNFR: In the study of Auricchio and colleagues (4), which compared pseudotyped AAV vector-mediated transduction of human placental alkaline phosphatase (hPALP) or erythropoietin of the murine lung, there was little or no detectable transgene expression after AAV[2/2] administration. These results are inconsistent with our data with mice and perhaps reflect differences in the pulmonary administration between the two studies. In the Auricchio study, the vector was administered to mice by nasal instillation, while in our study, endotracheal administration of the vector was employed. It is possible that the majority of AAV[2/2] vector delivered intranasally was trapped and bound to the nasal epithelium, thus significantly limiting transduction of the lung. Alternatively, it may be using different mouse strains that accounts for the disparity in the data. In our study, immunodeficient Rag-1 Ϫ/Ϫ mice were employed while in the Auricchio study, immunocompetent C57BL/6 mice were used. Taken together, the different results in rats and mice and between strains of mice highlight the limitations of animal studies and call for caution when drawing conclusions from studies carried in a single animal species.
What are the cells that are responsible for secretion of TNFR:Fc protein to the systemic circulation? Administration of AAV[2/2]CMV-EGFP or AAV[2/2]CMV-EGFP vector to the rat lung demonstrated differences in transduction efficiencies on a per-cell basis with AAV[2/5] being superior, but similar cell types were transduced by the two pseudotyped vectors. These included airway epithelial cells in trachea, bronchi, and bronchioles and cells in the alveoli, vascular endothelium, and vascular smooth muscle. The data in Fig. 1a show that a twofold decline in serum TNFR:Fc levels from peak expression at day 40 stretched over a period of 3 months, which is generally consistent with the half-life of airway epithelia. In addition, limiting TNFR:Fc expression primarily to the airway epithelia by substitution of the CC10 promoter for the CMV enhancer/promoter did not significantly change the level and duration of TNFR:Fc expression (Fig. 4) . These results are also in agreement with positive immunohistochemical detection of hPALP in both the gas-exchanging alveolar and the conducting airway epithelial cells after pulmonary administration of an AAV [2/5] pseudotyped vector carrying the hPALP gene under the CC10 promoter (4) . Following the decline of bulk secretion of TNFR:Fc protein, it was still detectable in the serum at low levels for an extended period. It is possible that the more long-lived cells in the lung, such as vascular smooth muscle cells, that are also transduced by AAV [2/5] are responsible for the low level of long-term production of TNFR:Fc protein in the lung.
Taken together, these results suggest that airway epithelia, either the conducting airways, the epithelial cells in the alveoli, or both, can serve as an efficient depot for production and secretion of TNFR:Fc protein to the bloodstream. Other cells with a longer half-life, such as vascular smooth muscle cells, may contribute to lower levels but longer-term production and secretion of TNFR:Fc protein to the circulation.
The studies reported here show that all pseudotyped vectors elicited serum anti-AAV capsid-neutralizing antibody response and that there was no cross-neutralization between AAV2 and AAV5 pseudotyped vectors. Nonetheless, AAV [2/5] could be successfully readministered to animals that were treated earlier with a vector of either the same serotype (AAV [2/5]) (Fig. 6a) , another serotype (AAV [2/2] or AAV[2/1]) ( Fig. 6b and c (Fig. 6b) and reinduce production and secretion of TNFR:Fc protein to levels similar to those in rats that were treated with AAV [2/5] for the first time. These results demonstrate that serum-neutralizing antibodies against AAV5, AAV2, and AAV1 capsids do not present a major barrier to repeat administration of AAV [2/5] vector to the lung. Our observation of successful readministration of AAV vectors of the same serotype to the lung in the presence of anti-capsid serum-neutralizing antibodies is consistent with those of previously published studies (4, 6) . As suggested by Beck and colleagues, the anticapsid neutralization assay measures a total serum antibody response, of which IgG is the predominant Ig species. In the absence of inflammation and capillary leakage of serum proteins, IgG is generally not available on the large airway surface to neutralize foreign antigens (6) . The predominant surface immunoglobulin is secretory IgA (31) . In this study, we did not directly measure secretory IgA, but the observation of successful readministration suggests the absence of such a response.
Following the initial pulmonary administration of AAV[2/5], peak serum TNFR:Fc protein expression was reached after 40 days (Fig. 1a) . However, upon readministration, the kinetics of transgene expression appeared different, since maximum serum TNFR:Fc protein levels were realized only after 203 days (Fig. 6a) . One explanation that may account for these differences is that the first administration of AAV [ 
